Cholangiocarcinoma - evolving concepts and therapeutic strategies
- PMID: 28994423
- PMCID: PMC5819599
- DOI: 10.1038/nrclinonc.2017.157
Cholangiocarcinoma - evolving concepts and therapeutic strategies
Abstract
Cholangiocarcinoma is a disease entity comprising diverse epithelial tumours with features of cholangiocyte differentiation: cholangiocarcinomas are categorized according to anatomical location as intrahepatic (iCCA), perihilar (pCCA), or distal (dCCA). Each subtype has a distinct epidemiology, biology, prognosis, and strategy for clinical management. The incidence of cholangiocarcinoma, particularly iCCA, has increased globally over the past few decades. Surgical resection remains the mainstay of potentially curative treatment for all three disease subtypes, whereas liver transplantation after neoadjuvant chemoradiation is restricted to a subset of patients with early stage pCCA. For patients with advanced-stage or unresectable disease, locoregional and systemic chemotherapeutics are the primary treatment options. Improvements in external-beam radiation therapy have facilitated the treatment of cholangiocarcinoma. Moreover, advances in comprehensive whole-exome and transcriptome sequencing have defined the genetic landscape of each cholangiocarcinoma subtype. Accordingly, promising molecular targets for precision medicine have been identified, and are being evaluated in clinical trials, including those exploring immunotherapy. Biomarker-driven trials, in which patients are stratified according to anatomical cholangiocarcinoma subtype and genetic aberrations, will be essential in the development of targeted therapies. Targeting the rich tumour stroma of cholangiocarcinoma in conjunction with targeted therapies might also be useful. Herein, we review the evolving developments in the epidemiology, pathogenesis, and management of cholangiocarcinoma.
Conflict of interest statement
R.K.K has received research support from Agios, Eli Lilly, Merck, and Novartis, via her institution, for conduct of clinical trials in cholangiocarcinoma. S.R., S.A.K., C.L.H., and G.J.G. declare no competing interests.
Figures
Similar articles
-
Emerging molecular therapeutic targets for cholangiocarcinoma.J Hepatol. 2017 Sep;67(3):632-644. doi: 10.1016/j.jhep.2017.03.026. Epub 2017 Apr 5. J Hepatol. 2017. PMID: 28389139 Free PMC article. Review.
-
New and Emerging Systemic Therapeutic Options for Advanced Cholangiocarcinoma.Cells. 2020 Mar 11;9(3):688. doi: 10.3390/cells9030688. Cells. 2020. PMID: 32168869 Free PMC article. Review.
-
The state of therapy modalities in clinic for biliary tract cancer.Front Biosci (Landmark Ed). 2022 Jun 8;27(6):185. doi: 10.31083/j.fbl2706185. Front Biosci (Landmark Ed). 2022. PMID: 35748261 Review.
-
Pathogenesis, diagnosis, and management of cholangiocarcinoma.Gastroenterology. 2013 Dec;145(6):1215-29. doi: 10.1053/j.gastro.2013.10.013. Epub 2013 Oct 15. Gastroenterology. 2013. PMID: 24140396 Free PMC article. Review.
-
Neoadjuvant therapy for cholangiocarcinoma: A comprehensive literature review.Cancer Treat Res Commun. 2021;27:100354. doi: 10.1016/j.ctarc.2021.100354. Epub 2021 Mar 16. Cancer Treat Res Commun. 2021. PMID: 33756174 Review.
Cited by
-
O-GlcNAcylation Facilitates the Interaction between Keratin 18 and Isocitrate Dehydrogenases and Potentially Influencing Cholangiocarcinoma Progression.ACS Cent Sci. 2024 Apr 23;10(5):1065-1083. doi: 10.1021/acscentsci.4c00163. eCollection 2024 May 22. ACS Cent Sci. 2024. PMID: 38799671 Free PMC article.
-
Notch signaling pathway in cancer: from mechanistic insights to targeted therapies.Signal Transduct Target Ther. 2024 May 27;9(1):128. doi: 10.1038/s41392-024-01828-x. Signal Transduct Target Ther. 2024. PMID: 38797752 Free PMC article. Review.
-
NEDD4 and NEDD4L: Ubiquitin Ligases Closely Related to Digestive Diseases.Biomolecules. 2024 May 13;14(5):577. doi: 10.3390/biom14050577. Biomolecules. 2024. PMID: 38785984 Free PMC article. Review.
-
High immune cell infiltration predicts improved survival in cholangiocarcinoma.Front Oncol. 2024 May 1;14:1333926. doi: 10.3389/fonc.2024.1333926. eCollection 2024. Front Oncol. 2024. PMID: 38751812 Free PMC article.
-
Transcription factor EHF drives cholangiocarcinoma development through transcriptional activation of glioma-associated oncogene homolog 1 and chemokine CCL2.MedComm (2020). 2024 May 13;5(5):e535. doi: 10.1002/mco2.535. eCollection 2024 May. MedComm (2020). 2024. PMID: 38741887 Free PMC article.
References
-
- Khan SA, et al. Changing international trends in mortality rates for liver, biliary and pancreatic tumours. J Hepatol. 2002;37:806–813. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous